Skip to main content

Certara, Inc. (CERT)

NASDAQ: CERT · IEX Real-Time Price · USD
36.00
0.00 (0.00%)
After-hours:Sep 24, 2021 4:04 PM EDT
36.00
-0.03 (-0.08%)
At close: Sep 24, 4:00 PM
Market Cap5.50B
Revenue (ttm)261.77M
Net Income (ttm)n/a
Shares Out152.86M
EPS (ttm)-0.39
PE Ration/a
Forward PE136.99
Dividendn/a
Ex-Dividend Daten/a
Volume1,437,531
Open35.84
Previous Close36.03
Day's Range35.55 - 36.63
52-Week Range23.75 - 41.79
Betan/a
AnalystsBuy
Price Target37.75 (+4.9%)
Est. Earnings DateNov 4, 2021

About CERT

Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, em...

IndustryBiotechnology
IPO DateDec 11, 2020
Employees846
Stock ExchangeNASDAQ
Ticker SymbolCERT
Full Company Profile

Financial Performance

In 2020, Certara's revenue was $243.53 million, an increase of 16.79% compared to the previous year's $208.51 million. Losses were -$49.40 million, 453.4% more than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for Certara stock is "Buy." The 12-month stock price forecast is 37.75, which is an increase of 4.86% from the latest price.

Price Target
$37.75
(4.86% upside)
Analyst Consensus: Buy

News

Certara Announces New Clinical Science Group and Adds Senior Scientific Experts

Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities

3 days ago - GlobeNewsWire

Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation

Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence

5 days ago - GlobeNewsWire

Certara Announces Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Pur...

PRINCETON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common stoc...

1 week ago - GlobeNewsWire

Certara Stock Under Pressure On Equity Raise Of $140M At 12% Discount

Certara Inc (NASDAQ: CERT) has priced its previously announced underwritten public offering of 4.5 million shares at $31.00 per share for gross proceeds of $139.5 million. The offer price represents a d...

2 weeks ago - Benzinga

Certara Announces Pricing of Public Offering of Common Stock

PRINCETON, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of shares of its commo...

2 weeks ago - GlobeNewsWire

Certara Announces Proposed Public Offering of Common Stock

PRINCETON, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering of 20,000,000 shares of its co...

3 weeks ago - GlobeNewsWire

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the foll...

3 weeks ago - GlobeNewsWire

Certara To Buy Compliance Software Provider For $310; Q2 Earnings Beat Expectations, Raises FY21 Guidance

Certara Inc (NASDAQ: CERT) has agreed to acquire Pinnacle 21 for $310 million in cash and stock.  Pinnacle 21's software tools are used to validate compliance to the Clinical Data Interchange Standards ...

1 month ago - Benzinga

Certara Reports Second Quarter 2021 Financial Results

Raises full year 2021 guidance and announces deal to acquire Pinnacle 21 Raises full year 2021 guidance and announces deal to acquire Pinnacle 21

1 month ago - GlobeNewsWire

Certara to Acquire Pinnacle 21, a Leader in Data Standardization Software for Pharmaceutical Clinical Data

Transaction expected to be accretive to Certara's revenue, revenue growth and adjusted EBITDA margin Transaction expected to be accretive to Certara's revenue, revenue growth and adjusted EBITDA margin

1 month ago - GlobeNewsWire

Mubadala Invests in Global Biosimulation Leader Certara

PRINCETON, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Certara (NASDAQ: CERT), a global leader in biosimulation, today announced that Mubadala Investment Company (Mubadala) has made an approximately $250 mi...

1 month ago - GlobeNewsWire

Certara's Vaccine Simulator™ Accurately Predicted Optimal Timing Between Doses for COVID-19

Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, Showcasing the Power of Biosimulation Technology Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, S...

2 months ago - GlobeNewsWire

Certara Appoints Nancy Killefer and Cynthia Collins as New Independent Board Members

PRINCETON, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced the appointments of Nancy Killefer and Cynthia Collins to its board of directors, effective ...

2 months ago - GlobeNewsWire

Certara to Report Second Quarter 2021 Financial Results on August 5, 2021

PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2021 a...

2 months ago - GlobeNewsWire

Certara Announces New Chief Human Resources Officer

Veteran HR leader brings 20+ years of human resources experience to the company's executive team Veteran HR leader brings 20+ years of human resources experience to the company's executive team

2 months ago - GlobeNewsWire

Certara Announces Update of BaseCase Software, the Company's Value Communication Platform

Major Release to Help Life Science Companies Maximize Go-to-Market Impact Major Release to Help Life Science Companies Maximize Go-to-Market Impact

2 months ago - GlobeNewsWire

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara's Biosimulation Software for Eva...

The PMDA enters 8th consecutive year of using Certara's biosimulation software The PMDA enters 8th consecutive year of using Certara's biosimulation software

3 months ago - GlobeNewsWire

Certara Appoints Dr. Carol Gallagher as New Independent Board Member

Dr. Gallagher brings more than 30 years of drug development and commercial leadership experience to her new role Dr. Gallagher brings more than 30 years of drug development and commercial leadership exp...

3 months ago - GlobeNewsWire

Certara to Participate in the William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference

PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick, Chie...

4 months ago - GlobeNewsWire

Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Dev...

Expanded capabilities in company's Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges Expanded capabilities in company's Immunogenicity...

4 months ago - GlobeNewsWire

Certara Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Guidance

PRINCETON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2021.

4 months ago - GlobeNewsWire

Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier

First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress First-of-its-kind software predicts likelihood of off-target safety issues that could imped...

4 months ago - GlobeNewsWire

Certara to Present at the BofA Securities 2021 Virtual Health Care Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Certara's CEO, William Feehery, and CFO, Andrew Schemick, are scheduled to present in the BofA Securities 2021 Virtual Health Care Conference.

4 months ago - Business Wire

Certara to Report Preliminary First Quarter 2021 Financial Results on May 6, 2021

PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that it will release preliminary financial results for the first quarter of 2021 after market close on May 6, 2021.

5 months ago - Business Wire

Certara Announces Closing of Public Offering of Common Stock

PRINCETON, N.J.--(BUSINESS WIRE)--Certara announced the closing of its underwritten public offering of its common stock at a public offering price of $25.00 per share.

5 months ago - Business Wire